ATHENS, Greece, Nov. 20, 2025 (GLOBE NEWSWIRE) — Diana Shipping Inc. (NYSE: DSX), (the “Company”), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels, today reported net income of $7.2 million and net income attributable to common stockholders of $5.7 million for the third quarter of 2025. This compares to a net income of $3.7 million and a net income attributable to common stockholders of $2.3 million for the third quarter of 2024. Earnings per share for the third quarter of 2025 were $0.05 basic and diluted, compared to $0.02 basic and $0.00 diluted in the same quarter of 2024. Time charter revenues were $51.9 million for the third quarter of 2025, compared to $57.5 million for the same quarter of 2024. The decrease in time charter revenues, compared to the same quarter last year,...

$4 billion in Minimum Contracted Revenue Gross Revenues of $577 million and net income of $103 million, or $2.75 per share $1.00 New Common Share Dividend, following $0.60 July 2025 Semi- Annual Payment Dynamic growth – 20 Vessel Total Newbuilding Program Including Three VLCCs Stronger Tanker Fundamentals Supported by Market Tightness and Geopolitics ATHENS, Greece, Nov. 20, 2025 (GLOBE NEWSWIRE) — TEN, Ltd (TEN) (NYSE: TEN) (the “Company”) today reported results (unaudited) for the nine months and third quarter ended September 30, 2025. NINE MONTHS 2025 SUMMARY RESULTSTEN’s fleet generated $577 million in gross revenues resulting in approx. $171 million in operating income inclusive of $12.5 million in capital gains from the sale of four older vessels. The net income for the first nine months of 2025 was $103 million or $2.75...

ROGERS, Ark., Nov. 20, 2025 (GLOBE NEWSWIRE) — America’s Car-Mart, Inc. (NASDAQ: CRMT) today announced it will release fiscal 2026 second quarter financial results on Thursday, December 4, 2025, before the market opens. A webcast and conference call will be held that same day at 9:00 a.m. ET to review the Company’s results. Participants may access the conference call via webcast using this link: Webcast Link Here. To participate via telephone, please register in advance using this Registration Link. Upon registration, all telephone participants will receive a one-time confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call. All participants are encouraged to dial-in 10 minutes prior to the start time. A replay of the conference call and...

Management to host conference call and webcast Thursday, November 20, 2025, at 8:30 AM ET Company advances commercialization and is on track to meet year-end system deployment target PETAH TIKVA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the third quarter ended September 30, 2025, and provided a business update. Recent Highlights:Generated $3.4 million in revenue in the third quarter of 2025, compared to $3.0 million in the third quarter of 2024. Acquired 100% of the stock of Vaso Healthcare IT, a provider of healthcare information technologies solutions, for cash and future operational based earnouts. Secured new commercial collaborations to accelerate commercialization of the Nanox.ARC and...

 —Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment Advances, with EMA Guidance Supporting a Single Nebokitug Phase 3 Registration Trial Using a Clinical Event Composite Endpoint— —Phase 2 SPRING Trial OLE Data Showing Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks Presented at AASLD 2025— —New Clinical Data Presented at AASLD 2025 Provides Insights on Nebokitug’s Direct Macrophage-Mediated Mechanisms that Are Relevant to Halting or Slowing PSC Disease Progression— —Multiple Partnering Options for Supporting the Nebokitug Phase 3 Program Continue to Advance— —Cash Runway Expected through End of Fourth Quarter of 2026— TEL AVIV, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) — Chemomab Therapeutics Ltd. (Nasdaq: CMMB),...

OR YEHUDA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) — Formula Systems (1985) Ltd. (Nasdaq and TASE: FORTY) (“Formula Systems,” or the “Company”), a global information technology group engaged, through its subsidiaries and affiliates, in providing software consulting services and computer-based business solutions and developing proprietary software products, today announced its third quarter and nine-months period ended September 30, 2025 results of operations. Financial Highlights for the Quarter Ended September 30, 2025On August 13, 2025, Sapiens International Corporation N.V, (hereafter “Sapiens”) announced that it has entered into a definitive agreement to be acquired by Advent, a leading global private equity investor, for $43.50 per common share, in an all-cash transaction. Under the terms of the agreement, the Company will...

CELEBRATION, Fla., Nov. 20, 2025 (GLOBE NEWSWIRE) — La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a real estate and PropTech company, today provided a business update and reported financial results for the third quarter ended September 30, 2025. Q3 2025 Financial HighlightsTotal revenue increased 3.2% year-over-year to $20.2 million for the third quarter ended September 30, 2025 from $19.6 million for the third quarter ended September 30, 2024. Residential real estate services revenue increased by approximately $286 thousand to $16.8 million, or 1.7% for the third quarter ended September 30, 2025 from $16.5 million for the third quarter ended September 30, 2024 Property management revenue increased by approximately $255 thousand to approximately $3.1 million, or 8.9%, for the third quarter ended September...

Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug’s commercial potential In September 2025, Sol-Gel announced Health Canada approval of EPSOLAY Sol-Gel signed an additional agreement with Viatris covering Australia and New Zealand for both EPSOLAY and TWYNEONESS ZIONA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced financial results for the third quarter ending September 30, 2025, and provided a corporate update. Q3 2025 and Recent Corporate DevelopmentsSol-Gel’s ongoing Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, for which top-line results...

Ongoing Enrollment Continues in VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Commissioning Completed for Expanded NexoBrid® Facility; Full Operational Capacity Expected by Year-End 2025 Balance Sheet Strengthened with $30 Million Equity Financing Third Quarter 2025 Revenue of $5.4 Million, Up 23% Year-over-Year Conference Call Today, November 20, 2025, at 8:30 a.m. Eastern Time YAVNE, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the third quarter ended September 30, 2025, and provided a corporate update. “We continued to execute our growth strategy this quarter, advancing both our operational capabilities and our late-stage clinical programs,” said Ofer Gonen, Chief Executive...

Launches the Consumer First Formula with four strategic priorities to drive sustainable long-term growth Third-quarter net sales of $1.6 billion, down 1%. Earnings per diluted share of $0.37; Adjusted earnings per diluted share of $0.35 Q4 and full-year 2025 guidance lowered reflecting current business trends and continuation of recent macro consumer pressuresCOLUMBUS, Ohio, Nov. 20, 2025 (GLOBE NEWSWIRE) — Bath & Body Works, Inc. (NYSE: BBWI) today reported third quarter 2025 results. Daniel Heaf, chief executive officer of Bath & Body Works, commented, “Today, we are excited to announce a comprehensive transformation plan to revitalize Bath & Body Works across brand, product, and marketplace. This plan, the Consumer First Formula, focuses our investments in our four largest revenue driving opportunities –...